PF-06463922
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for PF-06463922, covering 2015-12-04 to 2022-02-09. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) [Phase 1, Phase 2]